March Quarter 2025 Results May 15, 2025 Disclaimer This presentation contains certain financial measures that are not recognized under generally accepted accounting principles in the United States of America ("GAAP"), including adjusted EBITDA (including adjusted EBITDA margin), adjusted EBITA (including adjusted EBITA margin), non-GAAP net income, non-GAAP diluted earnings per share/ADS and free cash flow. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measur ...

ans Foot Locker ACQUISITION OF FOOT LOCKER MAY 15, 2025 0.00000000000000000000000000 ● ● ����������������������������� 0 0 . . ● ● .. . . . . . . 2 . 3 CREATING A GLOBAL LEADER IN THE SPORTS RETAIL INDUSTRY DICK®S $21B FY24 REVENUE 52 BBT 26 COUNTRIES 3.266 STORES "$300B FY24 TOTAL ADDRESSABLE GLOBAL MARKET ACROSS THE SPORTS RETAIL INDUSTRY DICK'S SPORTS CHANGE LIVES . . Represents a non-6AM ? Trancial measure. See the Company's website at investors.00CKS: con for a resonctiliation of this measure to the mo ...

Novavax Corporate Presentation May 2025 © 2025 NOVAVAX. All rights reserved. Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strat ...

Investor Presentation May 2025 Legal LGTM (PJR) 5.13.25 via Slack Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income from continuing operations, Adjusted SG&A, Adjusted SG&A as a percentage of revenue, Insurance BER (non-GAAP measures, as defined herein) ...

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. © 2025 4D Molecular Therapeutics. All Rights Reserved. 2 Bank of America 2025 Healthcare Conference Corporate Presentation May 2025 © 2025 4D Molecular Therapeutics. All Rights Reserved. © 2025 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of h ...

All statements in this presentation and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other ...

Financial Performance & Guidance - Q1 2024 revenue reached $25.7 million, a 6% increase year-over-year[18] - Remaining Performance Obligations (RPO) for Q1 2024 were $195.7 million, up 19% from Q1 2023[18] - Annual Recurring Revenue (ARR) for Q1 2024 was $120.9 million, a 15% increase year-over-year[18] - The company anticipates Q2 2024 revenue between $29.0 million and $33.0 million and full year 2024 revenue between $122.0 million and $132.0 million, representing a 20% improvement over 2023 at the midpoint[11, 27] - The company anticipates a Non-GAAP operating loss between ($3.0) million and $1.0 million for Q2 2024 and between ($11.0) million and ($1.0) million for full year 2024, a $19.8 million improvement at the midpoint[11, 27] - The company anticipates adjusted EBITDA between $2.0 million and $5.0 million for Q2 2024 and between $7.0 million and $15.0 million for full year 2024, a $22.0 million improvement at the midpoint[11, 27] Operational Highlights - Spire operates the largest multi-purpose constellation[9] - The company processes over 10 terabytes of data per day to feed AI/ML models[10] - The company raised $40 million gross proceeds at an average price of $13.44 per share in Q1[11] Market Trends & Opportunities - Climate change and global security challenges are driving demand for the company's business[6] - Underwriters have raised premiums for ships transiting the Red Sea by as high as 50% for U S, British, and Israeli firms[12]

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the heading "Risk Factors" contained in TMC's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 27, 2025, as well as any updates to those risk factors filed from time to time in TMC's subsequent periodic and current reports. All information in this present ...

Investor Update Presentation March 31, 2025 LOS ANGELES NEW YORK LONDON BAHRAIN ABU DHABI RIYADH DOHA MUMBAI DELHI BEIJING SINGAPORE TOKYO Investcorp Credit Management BDC, Inc. Forward-looking Statements and Disclosures Statements included in this presentation may contain "forward-looking statements," which relate to future performance or financial condition of Investcorp Credit Management BDC, Inc. ("ICMB"). Forward-looking statements are based on estimates, projections, beliefs and assumptions of ICMB's ...

2 Agenda First Quarter 2025 Results Arcos Dorados May 14, 2025 Disclaimer This presentation contains forward-looking statements that represent our beliefs, projections and predictions about future events or our future performance. Forward-looking statements can be identified by terminology such as "may," "will," "would," "could," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other similar expressions or phrases ...